the Certificate of Analysis is published on this product page.
Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
It is one of the most disruptive symptoms in ME/CFS, fibromyalgia, and long COVID / PASC
The American Diabetes Association's Standards of Medical Care in Diabetes does not list colorectal cancer risk as a consideration when prescribing GLP-1 receptor agonists
DRM reports receiving research support from Janssen, serving on advisory boards and as a consultant for Novo Nordisk, Novartis, Eli Lilly, Sanofi-Aventis, Janssen and Servier, and giving lectures for Novo Nordisk, Servier, Sanofi-Aventis, Eli Lilly, Novartis and Janssen